( 3 Minutes Read)
The single-dose approach could help improve treatment compliance, reduce resistance, and make malaria care more accessible in Africa’s most affected communities.
Doctors in Gabon say a new single-dose malaria treatment could help curb the disease’s growing resistance to existing drugs. Led by Dr. Ghyslain Mombo-Ngoma at the Medical Research Centre of Lambaréné, researchers tested a one-time treatment combining four widely available anti-malarial compounds — sulfadoxine, pyrimethamine, artesunate, and pyronaridine. The new drug cleared malaria parasites in 93% of patients, matching the success of the standard three-day regimen.
For many Gabonese, malaria remains a constant struggle. Libreville resident Julicia Nfono says the disease keeps coming back despite preventive measures.
Read Also:
https://trendsnafrica.com/sadc-released-us-1-million-to-zambia-for-malaria-matchbox/
According to Gabon’s National Malaria Control Program, the country recorded more than 154,000 cases in 2024, with children under five most affected. Program official Hugues Ronel Essanga Ngomo calls malaria “a major public health problem.”
